|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Painful Bladder Syndrome | |||||
| Interstitial Cystitis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Cystitis | |||||
| Cystitis, Interstitial | |||||
| Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Disease | |||||
| Pathologic Processes | |||||
| Urinary Bladder Diseases | |||||
| Urologic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Botulinum Toxin A (Botox) | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Botulinum Toxin Type A | |||||
| Botulinum Toxins | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Dyskinesia Agents | |||||
| Central Nervous System Agents | |||||
| Neuromuscular Agents | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| University of Washington | |||||
| Paul Allen Foundation | |||||